Glipada 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Glipada 50 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The medication is generally well tolerated, with the most common adverse effects including headache, nasopharyngitis, and mild gastrointestinal disturbances. Patients should be monitored for signs of pancreatitis and hypersensitivity reactions, although these are rare. Glipada 50 is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Dose adjustments may be necessary in patients with renal impairment. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and guide treatment modifications.